NT5E and Miyoshi myopathy: Microvesicles from MM patients have also been found to express functional adenosinergic ectoenzymes that can produce ADO from ATP and NAD+,57 while treatment in vivo with daratumumab can induce the release of microvesicles expressing CD38, among other molecules such as CD39, CD73, CD203a, PD‐L1, CD55, and CD59.58